Business Context and Reporting Period
This Form 8-K is a current report filed by Supernus Pharmaceuticals, Inc. on September 12, 2014. The filing addresses corporate governance matters specifically related to executive compensation arrangements rather than operational or financial performance results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement and contains no quantitative financial data.
Material Changes
The material change reported is an amendment to the company's Executive Retention Agreement. On September 12, 2014, the Compensation Committee of the Board of Directors approved a revision to Section 3(b) of the agreement originally filed on August 11, 2014. The amended agreement is attached as Exhibit 10.1.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, guidance, risks, contingencies, or unusual items. The document strictly reports the approval of the executive compensation amendment.
Key Facts for Investor Verification
- Verify the specific terms of the amendment to Section 3(b) of the Executive Retention Agreement by reviewing Exhibit 10.1.
- Confirm the identity of the executives covered by the amended retention agreement.
- Note that this filing does not impact the company's reported financial position or operating results.